Sarcomas constitute a rare and diverse group of mesenchymal tumours driven by distinct pathogenesis. Despite significant advances in the management of other cancer primaries, systemic therapy in sarcoma still relies on traditional chemotherapy regimens in most cases. As part of the growing effort to individualize therapy, sarcoma classification has been refined with the identification of new entities. In addition, treatment strategies as well as drug development are increasingly adapted to the specific histological subtype and to the molecular background of the tumour. Nevertheless, these approaches have shown effectiveness only in a limited subset of patients. Moving forward, the incorporation of high throughput technologies in clinical practice will undoubtedly advance individualized strategies in the management of sarcoma patients. The introduction of new clinical trial designs is necessary to evaluate and establish novel targeted therapies. Furthermore, the establishment of multifactorial risk classification models may inform personalized strategies in early stages by predicting relapse and/ or drug resistance; ultimately guiding the initial as well as subsequent lines of treatment. The characterization of the individual immune, genomic, epigenetic landscape can provide useful information to tailor therapies.
Precision oncology in the field of sarcoma presents unique challenges, which we aim to highlight in this special issue by assembling a coherent set of papers that move our understanding of precision medicine in sarcomas forward. Recently, the implementation of new technologies has enabled clinicians to distinguish genetically well-defined subsets of sarcomas. However, there are still no selective treatment strategies for many sarcoma patients. Ongoing researches are likely to uncover more and more data that will help the understanding of the obstacles on the road to an effective biomarker-driven-care strategy for sarcoma patients.
We welcome various types of contributions including original research articles, review articles, brief communication, opinions, and case reports that explore the current landscape of precision medicine in sarcomas; all in the context of diagnosis, prognosis, and therapy. Scope and topics include but not limited to the following:
- Evolving strategies in diagnosis and classification.
- Biomarker-driven clinical care of patients with sarcomas.
- Novel therapeutic approaches that target the immune system.
- Therapeutic approaches targeting oncogenic drivers and other molecular alterations.
- Pharmacogenetics and pharmacokinetic guided therapy.
- Real-world evidence of precision oncology in sarcomas.
- Precision medicine trials in sarcomas.
- Artificial intelligence and computational approaches in the sarcoma field.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Sarcomas constitute a rare and diverse group of mesenchymal tumours driven by distinct pathogenesis. Despite significant advances in the management of other cancer primaries, systemic therapy in sarcoma still relies on traditional chemotherapy regimens in most cases. As part of the growing effort to individualize therapy, sarcoma classification has been refined with the identification of new entities. In addition, treatment strategies as well as drug development are increasingly adapted to the specific histological subtype and to the molecular background of the tumour. Nevertheless, these approaches have shown effectiveness only in a limited subset of patients. Moving forward, the incorporation of high throughput technologies in clinical practice will undoubtedly advance individualized strategies in the management of sarcoma patients. The introduction of new clinical trial designs is necessary to evaluate and establish novel targeted therapies. Furthermore, the establishment of multifactorial risk classification models may inform personalized strategies in early stages by predicting relapse and/ or drug resistance; ultimately guiding the initial as well as subsequent lines of treatment. The characterization of the individual immune, genomic, epigenetic landscape can provide useful information to tailor therapies.
Precision oncology in the field of sarcoma presents unique challenges, which we aim to highlight in this special issue by assembling a coherent set of papers that move our understanding of precision medicine in sarcomas forward. Recently, the implementation of new technologies has enabled clinicians to distinguish genetically well-defined subsets of sarcomas. However, there are still no selective treatment strategies for many sarcoma patients. Ongoing researches are likely to uncover more and more data that will help the understanding of the obstacles on the road to an effective biomarker-driven-care strategy for sarcoma patients.
We welcome various types of contributions including original research articles, review articles, brief communication, opinions, and case reports that explore the current landscape of precision medicine in sarcomas; all in the context of diagnosis, prognosis, and therapy. Scope and topics include but not limited to the following:
- Evolving strategies in diagnosis and classification.
- Biomarker-driven clinical care of patients with sarcomas.
- Novel therapeutic approaches that target the immune system.
- Therapeutic approaches targeting oncogenic drivers and other molecular alterations.
- Pharmacogenetics and pharmacokinetic guided therapy.
- Real-world evidence of precision oncology in sarcomas.
- Precision medicine trials in sarcomas.
- Artificial intelligence and computational approaches in the sarcoma field.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.